Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
Semenogelin (SEMG) I is a Cancer-Testis (CT) antigen that we have found to be expressed in myeloma cells. In this study, we set out to determine whether the expression of SEMG I could be upregulated pharmacologically. We found that SEMG I expression in myeloma cells can be upregulated by 5-azacytidine, IL-4 and IL-6. The mechanisms of SEMG I gene upregulation by 5-azacytidine is unclear since there was no correlation between the methylation of the single CpG dinucleotide at position -11 and SEMG I expression. Both IL-4 and IL-6 appeared to enhance SEMG I expression through increasing its promoter function.
Zhang
Yana
Y
Cancer Research Program, Harrington Regional Medical Center, Amarillo, TX, USA.
Wang
Zhiqing
Z
Zhang
Jian
J
Farmer
Benjamin
B
Lim
Seah H
SH
D001374:Azacitidine / Q000494:pharmacology; D001853:Bone Marrow / Q000473:pathology; D016207:Cytokines / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D008297:Male; D009101:Multiple Myeloma / Q000235:genetics* / Q000473:pathology; D010957:Plasmids; D011401:Promoter Regions, Genetic; D015183:Restriction Mapping; D012661:Semen / Q000502:physiology; D029607:Seminal Vesicle Secretory Proteins / Q000187:drug effects / Q000235:genetics*; D014162:Transfection; D015854:Up-Regulation
D016207:Cytokines; D015850:Interleukin-6; D029607:Seminal Vesicle Secretory Proteins; C424482:seminal vesicle-specific antigen; D015847:Interleukin-4; D001374:Azacitidine